Collegium Pharmaceutical, Inc. COLL

COLL Company Overview

Collegium Pharmaceutical, Inc. is a U.S.-based specialty pharmaceutical company focused on developing, manufacturing, and commercializing medications for serious medical conditions, with a primary emphasis on pain management. The company operates within the branded pharmaceutical and specialty therapeutics industries and derives most of its revenue from prescription pain therapies marketed to healthcare providers, pharmacies, payers, and health systems. Its portfolio includes extended-release and immediate-release opioid formulations as well as non-opioid pain products intended for chronic and acute pain treatment. Revenue is primarily generated through sales of branded prescription products in the United States.

The company’s core commercial products include Xtampza ER, an abuse-deterrent extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta ER and Nucynta IR, tapentadol-based pain medications acquired through acquisition activity. Collegium has positioned itself around differentiated pain therapies with abuse-deterrent or clinically distinct characteristics, a strategy aimed at addressing concerns surrounding opioid misuse while maintaining physician demand for pain management options. Founded in 2002 and headquartered in Stoughton, Massachusetts, the company evolved from a development-stage pharmaceutical business into a commercial specialty pharma company through product launches, licensing arrangements, and acquisitions that significantly expanded its marketed portfolio.